Three of the four PARPi used to validate the competitive growth assay are FDA approved for the treatment of BRCA1/2 negative breast and/or ovarian cancers (olaparib, niraparib and talazoparib) [18–20]. Here, BRCA1 is linked to ovarian carcinoma.